Search - tctmd.com

Displaying 401 - 420 of 1583

Sort: Relevancy | Date

News Daily News

Drugs to Tweak RAAS Response No Help in Acute COVID-19, RCTs Show

Caitlin E. Cox

April 19, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Daily News

Moderate-Intensity Exercise Possible For Patients With Statin Side Effects

Michael O'Riordan

April 03, 2023

News Daily News

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

Yael L. Maxwell

April 03, 2023

News Opinion CV Team Dispatch

April 2023 News Roundup

L.A. McKeown

April 01, 2023

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

Todd Neale

March 15, 2023

News Opinion CV Team Dispatch

March 2023 News Roundup

L.A. McKeown

March 15, 2023

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Conference News ACC 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

L.A. McKeown

March 14, 2023

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Caitlin E. Cox

March 14, 2023

News Conference News ACC 2023

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Michael O'Riordan

March 13, 2023

News Conference News ACC 2023

Tailored Alerts Up High-Intensity Statin Prescribing: PCDS Statin

Yael L. Maxwell

March 13, 2023

News Conference News ACC 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Todd Neale

March 10, 2023

News Conference News ACC 2023

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

Michael O'Riordan

March 10, 2023

News Conference News ACC 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Michael O'Riordan

March 09, 2023

News Conference News ACC 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

Todd Neale

March 08, 2023

News Conference News ACC 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Yael L. Maxwell

March 07, 2023

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

Presentation ACC 2023

A Randomized Trial Assessing The Impact Of Eliminating Copayment For High Value Preventive Medications For Low-income Seniors With Cardiovascular-related Chronic Diseases

Presenter: Braden Manns

March 06, 2023

Presentation ACC 2023

The STELLAR Phase 3 Trial: A Study of Sotaterceptin Combination with Background Therapy for the Treatment of Pulmonary Arterial Hypertension

Presenter: Marius M. Hoeper

March 05, 2023

Advertisement

Drugs to Tweak RAAS Response No Help in Acute COVID-19, RCTs Show

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

Moderate-Intensity Exercise Possible For Patients With Statin Side Effects

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

April 2023 News Roundup

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

March 2023 News Roundup

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Tailored Alerts Up High-Intensity Statin Prescribing: PCDS Statin

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

A Randomized Trial Assessing The Impact Of Eliminating Copayment For High Value Preventive Medications For Low-income Seniors With Cardiovascular-related Chronic Diseases

The STELLAR Phase 3 Trial: A Study of Sotaterceptin Combination with Background Therapy for the Treatment of Pulmonary Arterial Hypertension

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content